에 대한 최신 뉴스 Illumina (NASDAQ:ILMN) 주식

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

DXCM

ILMN

MRNA

NVDA

S&amp;P 500과 나스닥 100이 월요일 상승세를 이어갔다. 이로써 두 지수는 모두 8일 연속으로 상승을 기록하며 연방준비제도(연준)의 금리 인하를 앞두고 미국 경제 전망과 금융 상황이 개선됨에 따라 트레이더들이 낙관론을 유지하고 있는 것을 보여준다.

S&amp;P 500과 나스닥 100은 월가의 불안감이 사라져 8일 연속 상승: 월요일의 상승 주식

News

Movers

COHR

COIN

CRWD

ESTC

GWRE

PLTR

RDDT

SAIA

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 가이드와이어 소프트웨어(NYSE:GWRE)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 상향 조정했다. 

Arm과 보잉은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 1일-6월 7일)

Markets

Tech

Trading Ideas

ADTN

DELL

GDDY

HOUS

S&amp;P 다우존스 지수는 금요일 늦게 분기별 재조정에 맞춰 다양한 S&amp;P 지수에 대한 변경 사항을 발표했다. 유명한 S&amp;P 500 지수에 추가된 기업들 중 주목할만한 것은 사이버 보안 회사인 크라우드스트라이크(NASDAQ:CRWD)이다.

S&amp;P 500 지수의 분기별 재조정으로 크라우드스트라이크, KKR 및 고대디가 신규 편입

Illumina Inc

Illumina Inc COM-WHEN ISSUED

ILLUMINA ORD

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 11.9% on an annualized basis producing an average annual return of 20.33%. Currently, Illumina has a market capitalization of $20.38 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $4,050.72 today based on a price of $127.97 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727805627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) announced that the FDA issued a complete response letter&nbsp;to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis.
Shares of the company were down 6.1% on Sept. 19 following the announcement of the news.
Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach&#39;s ability to empty its contents. The FDA has not approved any effective medicine for treating gastroparesis in more than 40 years.
Year to date, shares of Vanda have increased 10.2% compared with the industry&#39;s rise of 0.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4a/78570.jpg?v=840412258" />
Image Source: Zacks Investment Research
<h2>More on FDA&#39;s CRL for VNDA&#39;s Tradipitant</h2>
Per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease.
Also, per management, the FDA delayed its decision by more than 185 days and failed to meet the requirements specified by the Food Drug and Cosmetic Act (FDCA).
Notably, the FDCA requires that the FDA review an NDA and provide either an approval or a possible hearing within 180 days of the filing. The FDA failed to do either.
Per the company, it had time and again asked the FDA to hold an advisory committee meeting to discuss the NDA for tradipitant while the regulatory body declined.
Several patients treated with tradipitant have now filed a Citizen Petition pleading with the regulatory body to approve tradipitant for the treatment of gastroparesis.
<h2>VNDA&#39;s Development Plans for Tradipitant</h2>
Despite the FDA declining to approve tradipitant for treating symptoms in gastroparesis, the company will continue to pursue the marketing approval for tradipitant in the given indication.
Apart from gastroparesis, VNDA is also developing tradipitant for preventing vomiting induced by motion sickness.
In May 2024, the company announced positive data from a second phase III study that investigated tradipitant for preventing vomiting induced by motion sickness.
Vanda plans to submit an NDA for tradipitant to the FDA for the treatment of motion sickness later in 2024.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Vanda currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.84 to $3.63. Earnings per share estimates for 2025 have improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 3.5%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.7%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 48.9%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2339326/vnda-stock-down-as-fda-rejects-nda-for-tradipitant-in-gastroparesis?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2339326">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Penny Stocks

Small Cap

Management

Analyst Ratings

General

FULC

KRYS

VNDA

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

EXAS

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) plunged 61.1% on Sept. 12 after the company announced disappointing top-line data from the phase III REACH study, which evaluated its pipeline candidate, losmapimod, for treating patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating disease.
Currently, there are no treatments approved for the given indication.
The study did not meet its primary endpoint as treatment with losmapimod failed to demonstrate a change from baseline in relative surface area (RSA), a measure of reachable workspace (RWS), compared with placebo at week 48.
The study also failed to achieve nominal statistical significance on the secondary endpoints.
Year to date, shares of Fulcrum have plunged 49% compared with the industry&#39;s decline of 0.8%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ab/77679.jpg?v=1785498249" style="height:371px; width:592px" />
Image Source: Zacks Investment Research
<h2>Data From FULC&#39;s REACH study</h2>
Data from the REACH study showed that treatment with losmapimod led to a 0.013 improvement in RSA compared to a 0.010 improvement in RWS for patients who received a placebo at week 48. This was the study&#39;s primary endpoint.
Also, patients receiving losmapimod demonstrated an increase of 0.42% in muscle fat infiltration while an increase of 0.57% in MFI was observed for patients who received placebo at week 48.
Meanwhile, patients who were treated with losmapimod demonstrated a 9.63% improvement in abductor strength compared with a 2.24% improvement in the placebo arm.
There were no statistically significant differences observed in the two patient-reported outcomes secondary endpoints of the REACH study.
Following the disappointing data observed in the REACH study, FULC decided to stop the further development of losmapimod in FSHD.
<h2>What&#39;s Next for FULC in Terms of Pipeline Development</h2>
Fulcrum is developing another pipeline candidate, pociredir, in an early-stage study for treating patients with sickle cell disease, an inherited blood disorder. The phase Ib PIONEER study evaluates pociredir in SCD.
The FDA has already granted a Fast Track designation and Orphan Drug designation to pociredir for the treatment of patients with SCD.
SCD has a significant unmet medical need, and if successfully developed and upon potential approval, pociredir has the potential to boost FULC&#39;s prospects in the days ahead.
As of June 30. 2024, Fulcrum had $273.8 million in cash, cash equivalents and marketable securities. The company plans to use the funds to advance pociredir in the treatment of SCD and other pipeline development activities.
<h2>Zacks Rank &amp; Other Stocks to Consider</h2>
Fulcrum currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) and Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), each sporting a Zacks Rank #1 at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.43. Year to date, shares of ILMN have lost 9.3%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.7%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
<a href="https://www.zacks.com/stock/news/2336049/fulc-stock-falls-as-muscle-disorder-study-misses-primary-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336049">To read this article on Zacks.com click here.</a>

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 11.63% on an annualized basis producing an average annual return of 19.91%. Currently, Illumina has a market capitalization of $19.94 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $37,705.05 today based on a price of $125.16 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726083015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $38,000 Today

Shares of Immunovant (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imvt#NASDAQ">IMVT</a>) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves&#39; Disease.
<h2>IMVT&#39;s Batoclimab Shows Superior Efficacy in GD Patients</h2>
The enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs therapy.&nbsp;Patients were then treated with the high batoclimab dose, 680 mg weekly subcutaneous injection, for 12 weeks, followed by another 12 weeks of lower batoclimab dose, 340 mg weekly SC.
The data showed that treatment with the batoclimab 680 mg dose led to a mean Immunoglobin G (IgG) reduction of 77%, translating to a Response rate of 76% in the GD patient population after 12 weeks. Additionally, it was observed that at the end of the first 12 weeks, 56% of the patients treated with the high-dose of the candidate achieved an ATD-Free Response.
During the next 12 weeks of treatment with the batoclimab 340 mg dose, the mean IgG&nbsp;level was further reduced by 65%, with a correspondingly lower responder rate of 68%. Additionally, the ATD-Free Response rate dropped to 36% in the second 12 weeks.
Patients who experienced at least a 70% IgG reduction by the end of the study had an ATD-Free Response rate nearly three times higher than those who did not (60% and 23%, respectively).
Year to date, shares of Immunovant have plunged 19.2% compared with the industry&#39;s 2.8% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/cd/76945.jpg?v=1496532795" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Along with the data readout, Immunovant also revealed data from multiple proprietary market research studies, highlighting a persistent unmet need among patients treated with ATDs who are either intolerant to, uncontrolled or have relapsed after treatment with the same.&nbsp;&nbsp;
Per IMVT, real-world claims data shows that 25-30% of GD patients remain uncontrolled on ATDs each year, with few treatment options available. This presents a valuable commercial opportunity for the company with little competition.
<h2>IMVT&#39;s Future Development Plans in Autoimmune Diseases</h2>
Leveraging the encouraging results from the phase IIa GD study ofbatoclimab, Immunovant is currently gearing up to initiate a pivotal study of its lead candidate, IMVT-1402, a novel and fully-human monoclonal antibody, for the same indication by the end of 2024.
In the press release, the company has also announced that it has aligned with the FDA regarding the impending pivotal study design and secured investigational new drug application clearance for IMVT-1402 to treat GD.
Apart from the GD study, separate mid to late-stage studies are also currently ongoing, evaluating batoclimab for the treatment of other autoimmune indications, like Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and thyroid eye disease. Subject to positive data from these studies, Immunovant plans to study IMVT-1402 for each of the above indications.
The company is on track to initiate four to five potentially registrational programs for IMVT-1402 over the next fiscal year (ending March 31, 2025). Over the next two fiscal years, the company plans to initiate studies in a total of 10 indications for IMVT-1402. The company also expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies.
<div class="chart_embed">
<h2>Immunovant, Inc. Price and Consensus</h2>
<img alt="Immunovant, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/9c/1725883442.png" style="height:310px; width:600px" title="" />
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
</div>
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Immunovant currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are&nbsp;Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>),&nbsp;Krystal Biotech, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and&nbsp;Fulcrum Therapeutics, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10,7%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.5%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.5%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2333347/imvt-stock-up-on-upbeat-data-from-graves-disease-study-of-batoclimab?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2333347">To read this article on Zacks.com click here.</a>

IMVT

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Shares of Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) have gained 46.2% in the past six months against the industry&#39;s decline of 2%.
The company&#39;s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing&#39;s syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters.
The company is also making good progress with its promising set of pipeline candidates.
<h2>Factors Driving CORT Stock in the Given Time Frame</h2>
Corcept has made steady progress with the development of its lead pipeline candidate, relacorilant, which is being evaluated in the phase III GRACE study for the treatment of Cushing&#39;s syndrome, also known as hypercortisolism.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/1c/76375.jpg?v=14044768" />
Image Source: Zacks Investment Research
The GRACE study comprises two parts &mdash; the open-label portion and the randomized withdrawal phase. In May 2024, CORT announced that the GRACE study met the primary endpoint in the randomized withdrawal phase. Data from the same showed that patients who were treated with relacorilant experienced loss of blood pressure control, the study&#39;s primary endpoint, versus placebo.
In April, the company announced data from the open-label phase of the GRACE study, which showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia, as well as other symptoms.
Per management, the GRACE study meeting the primary endpoint is a significant step forward in the development path for relacorilant as a treatment for Cushing&#39;s syndrome. A new drug application for relacorilant is likely to be submitted in the fourth quarter of 2024.
The candidate is also being evaluated in the phase III GRADIENT study for treating patients whose Cushing&#39;s syndrome is caused by adrenal adenoma. Data from the same is expected in the fourth quarter of 2024.
Corcept is also studying relacorilant in combination with other therapies for treating different cancer indications. The successful development of relacorilant will be an added boost to the company.
<h2>Korlym Drives Revenues for CORT</h2>
Corcept&#39;s top line solely comprises product sales from Korlym. The drug has been a consistent revenue driver for the company since approval. Sales of the drug increased 39.1% year over year to $310.6 million in the first half of 2024, owing to the strong demand and a record number of patients receiving the medication.
The company increased its annual revenue guidance for Korlym concurrently with second-quarter results. The company now expects total revenues in the range of $640-$670 million compared with the earlier projection of $620-$650 million.
The strong demand for Korlym is likely to continue the momentum for Corcept for the remainder of 2024. Also, a potential approval for relacorilant should help the company address a broader patient population, which should push the stock upward in the future quarters.
<div class="chart_embed">
<h2>Corcept Therapeutics Incorporated Price</h2>
<img alt="Corcept Therapeutics Incorporated Price" src="https://staticx-tuner.zacks.com/images/charts/2c/1725369636.png" style="height:251px; width:538px" title="" />
Corcept Therapeutics Incorporated price | Corcept Therapeutics Incorporated Quote
</div>
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Corcept currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the drug/biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Bioventus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bvs#NASDAQ">BVS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Bioventus&#39; 2024 earnings per share have increased from 27 cents to 40 cents. Earnings per share estimates for 2025 have improved from 43 cents to 45 cents. Year to date, shares of BVS have risen 90.7%.
BVS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 102.86%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330901/corcept-shares-rise-more-than-45-in-six-months-here-s-why?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2330901">To read this article on Zacks.com click here.</a>

CORT

Corcept Shares Rise More Than 45% in Six Months: Here's Why

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.
The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in the overall population as well as the monotherapy population.
However, as a component of the primary endpoint, treatment with vutrisiran led to a 30% reduction in mortality in the monotherapy population in the double-blind period. Per management, this reduction was non-significant.
This might have hurt investors&#39; sentiments and resulted in the stock going down.
<h2>ALNY Stock Outperforming Industry</h2>
Shares of Alnylam have gained 37.3% so far this year compared with the industry&#39;s growth of 0.6%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/76266.jpg?v=875498674" />
Image Source: Zacks Investment Research
Please note that vutrisiran is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. This is also approved in the European Union for the same indication in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is marketed under the trade name Amvuttra in the United States and Europe.
In June 2024, Alnylam reported encouraging data from the phase III HELIOS-B study evaluating vutrisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. Shares of the company soared on this news.
The phase III HELIOS-B study enrolled 655 adult patients with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy who were divided equally to receive vutrisiran 25mg or placebo subcutaneously once every three months for up to 36 months.
Alnylam is gearing up to proceed with global regulatory submissions, including filing a supplemental new drug application for vutrisiran with the FDA using a Priority Review Voucher later in 2024.
<h2>Amvuttra, a Key Revenue Driver for ALNY</h2>
Amvuttra is currently the top contributor to Alnylam&#39;s top line. This drug generated sales worth $425.4 million in the first half of 2024, increasing 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from ALNY&#39;s Onpattro(patisiran).
Onpattro is also approved in the United States and European Union to treat ATTR amyloidosis in adults.
If approved forthe new indication, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR amyloidosis with cardiomyopathy. This is likely to boost sales further and will expand the eligible patient population for the drug in future quarters.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330592/alny-down-despite-positive-data-from-heart-disease-drug-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2330592">To read this article on Zacks.com click here.</a>

ALNY

ALNY Down Despite Positive Data From Heart Disease Drug Study

Provider of DNA sequencing and array-based technologies, Illumina, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) said it welcomes the European Court of Justice&#8217;s (ECJ&#8217;s) judgment ruling that the European Commission did not have jurisdiction over Illumina&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40680742/european-court-of-justice-rules-in-favor-of-illumina-in-jurisdictional-appeal" rel="noreferrer noopener">acquisition of GRAIL</a>.
The judgment confirms Illumina&#8217;s longstanding view that the European Commission exceeded its authority by asserting jurisdiction <a target="_blank" href="https://www.benzinga.com/markets/equities/23/12/36202820/illumina-versus-european-commission-legal-battle-over-grail-acquisition-reaches-critical-stage" rel="noreferrer noopener">over this merger</a>.
The basis for the&nbsp;$476.96 million (432 million euro)&nbsp;fine has been removed and will no longer be payable.
Following Illumina&#8217;s spinoff of GRAIL Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) in&nbsp;June 2024, GRAIL is now an <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39474696/once-valued-at-around-7b-cancer-blood-test-developer-grail-to-kickstart-trading-on-nasdaq" rel="noreferrer noopener">independent public company</a>.
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/b39465729/grail-to-begin-trading-on-the-nasdaq-stock-exchange" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;
In July 2021, Illumina said it was committed to <a href="https://www.benzinga.com/government/21/07/22128324/illumina-grail-8b-merger-hit-by-european-commissions-in-depth-investigation" target="_blank" rel="noreferrer noopener">re-acquiring Grail</a>. Illumina maintains a minority share of 14.5% in GRAIL.
&#8220;The Commission is not authorized to encourage or accept referrals of proposed concentrations without a European dimension from national competition authorities where those authorities are not competent to examine those proposed concentrations under their own national law,&#8221; Reuters highlighted, citing CJEU judges.
In the U.S., the FTC Commissioners dismissed the case against Illumina and GRAIL on&nbsp;August 15, 2024, following the spinoff of GRAIL, thus ending the US proceedings.
In a setback for EU antitrust regulators, in March, an adviser to Europe&#8217;s top court criticized the decision to block&nbsp;Illumina&#8217;s $7.1 billion bid for&nbsp;Grail, stating that they&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37877811/eu-antitrust-regulators-overstepped-in-illumina-grail-deal-says-court-adviser" rel="noreferrer noopener">exceeded their powers</a>.&nbsp;
Following requests from several EU countries, the European Commission invoked Article 22 in 2021 to assess the Illumina-Grail deal despite it falling below the EU merger revenue threshold.&nbsp;
In July, Illumina acquired&nbsp;Fluent BioSciences to expand its reach in single-cell analysis and&nbsp;multiomics research for an&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39716150/whats-going-on-with-10x-genomics-stock-on-wednesday" rel="noreferrer noopener">undisclosed consideration</a>.
Price Action: ILMN stock is up 1.11% at $132.86 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40684403/sanofi-still-bets-on-multiple-sclerosis-med-tolebrutinib-despite-the-investigational-drug-fell-sh" target="_blank" rel="noreferrer noopener">Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials</a>.</li>
</ul>
Photo via Shutterstock

Health Care

Legal

GRAL

European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.
Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed and will no longer be payable.
Following Illumina's spin-off of GRAIL in June 2024, GRAIL is now an independent public company. Illumina maintains a minority share of 14.5% in GRAIL, and Illumina will continue to support the company with its sequencing technology and suite of services.
In the US, the FTC Commissioners dismissed the case against Illumina and GRAIL on August 15, 2024, following the successful spinoff of GRAIL, thus ending the US proceedings.

Government

Regulations

Illumina Hails ECJ Ruling, Eliminates €432M Fine Over GRAIL Acquisition

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has fallen 9.67% since its last report. The company recently reported that it has 4.21 million shares sold short, which is 2.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725303620_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 5.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Illumina's Recent Short Interest

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 12.08% on an annualized basis producing an average annual return of 20.4%. Currently, Illumina has a market capitalization of $20.98 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $42,473.66 today based on a price of $131.70 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724877029_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today

Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) has secured the FDA&#39;s approval for its in vitro diagnostic (IVD) TruSight Oncology&nbsp;Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient&#39;s solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
The latest development marks a long-awaited milestone for the company&#39;s oncology customers and community. In Europe, a separate CE-marked version of TSO Comprehensive has been available since its launch in 2022.&nbsp;
<h2>Role of ILMN&#39;s TSO Comprehensive Test as a CDx</h2>
A CDx test can reveal whether a patient&#39;s tumor has a specific gene change or biomarker that can be targeted by a therapy, helping to determine if a patient should receive the treatment. Illumina&#39;s TSO Comprehensive is FDA-approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer&#39;s VITRAKVI (larotrectinib). VITRAKVI is a highly selective TRK inhibitor approved for use in patients with TRK fusion cancer, in accordance with therapeutic labeling.
NTRK gene fusions are rare across most solid cancer tumor types (~0.1%&ndash;0.3%) and can be challenging to detect, given that these genes can fuse with different partners, many of which were previously unknown. TSO Comprehensive interrogates ribonucleic acid and can identify a broad range of known and novel gene fusion partners across all three NTRK gene fusions, NTRK1, NTRK2 and NTRK3.
Most CDx tests are specific to one type of cancer, however, TSO Comprehensive is approved for use across solid tumor indications for the NTRK CDx. This helps to maximize the chances of finding actionable information from each patient&#39;s biopsy.
<h2>Importance of ILMN&#39;s TSO Comprehensive in NSCLC Treatment</h2>
The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Eli Lilly&#39;s RETEVMO (selpercatinib) &mdash; a highly selective and potent RET kinase inhibitor in locally advanced or metastatic NSCLC.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6a/75694.jpg?v=224811459" />
Image Source: Zacks Investment Research
As one of the most common types of lung cancer and the leading cause of cancer-related deaths globally, NSCLC has an expansive actionable biomarker landscape. This has driven the need for broad molecular profiling to better understand the patient&#39;s disease and guide clinical management. The oncogenic activation of RET fusion-positive NSCLC by gene fusions is a primary driver in NSCLC, occurring in up to 2% of cases.
TSO Comprehensive enables broad characterization and simultaneous detection of multiple prognostic and predictive biomarkers such as RET, genomic signatures such as tumor mutational burden and emerging biomarkers within NSCLC in a single test.
<h2>Collaborations Boost Illumina&#39;s Cancer Efforts</h2>
Illumina&#39;s partnerships with industry leaders like Bayer and Lilly are crucial to advancing cancer diagnostics and expanding access to precision oncology for more patients. The company is developing a pipeline of CDx claims through partnerships with pharmaceutical companies, which will be added to TSO Comprehensive following appropriate regulatory approvals. These CDx claims will help unlock groundbreaking targeted therapies and immunotherapies to benefit cancer patients.
TSO Comprehensive will start shipping to customers this year. Comprehensive genomic profiling assays with CDx claims for solid tumors, like TSO Comprehensive, are reimbursable under Centers for Medicare &amp; Medicaid Service national coverage determination.
<h2>Industry Prospects Favors Illumina</h2>
Per a Grand View Research report, the global oncology CDx market was valued at $4.78 billion in 2023 and projected to grow at a compound annual growth rate (CAGR) of 8.7% by 2030.
The market is growing due to the increasing prevalence of cancer, the growing adoption of CDx and a rising emphasis on personalized medicine. The need for early cancer detection tests, which can help improve disease management &amp; reduce mortality, is expected to propel the overall market growth.
<h2>Illumina&#39;s Recent Developments</h2>
Earlier this month, the company expanded its oncology menu for the NovaSeq X Series customers with the high-throughput version of TruSight Oncology 500 and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times and broader batch sizes on the NovaSeq X Series for the first time.
<h2>ILMN Stock Price, Consensus and EPS Surprise</h2>
In the past year, ILMN shares have lost 17.2% compared with the industry&#39;s decline of 2.3%.
In the past 30 days, Illumina&#39;s 2024 estimated earnings have surged nearly 94% to $3.16 per share. The stock has beat estimates in each of the trailing four quarters, the average surprise being 463.5%.
<h2>ILMN&#39;s Zacks Rank and Other Top MedTech Stocks</h2>
Illumina currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>), Boston Scientific and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Exact Sciences&#39; shares have lost 25.2% in the past year. Estimates for the company&#39;s loss per share have improved from $1.09 to 95 cents in 2024 and from 26 cents to 6 cents in 2025 in the past 30 days. EXAS&#39; earnings beat estimates in three of the trailing four quarters and matched in one, delivering an average surprise of 56.2%. In the last reported quarter, it posted an earnings surprise of 75.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved to $2.40 from $2.36 in the past 30 days. Shares of the company have gained 48.1% in the past year compared with the industry&#39;s growth of 13.9%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for SiBone&#39;s 2024 loss per share have narrowed to 89 cents from 95 cents in the past 30 days. Shares of the company have lost 23% in the past year against the industry&#39;s 11.4% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2328511/ilmn-s-tso-comprehensive-ivd-test-secures-fda-approval-as-cdx?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328511">To read this article on Zacks.com click here.</a>

SIBN

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

Argus Research analyst Jasper Hellweg upgrades Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Hold to Buy and announces $150 price target.

Upgrades

Price Target

Argus Research Upgrades Illumina to Buy, Announces $150 Price Target

<ul>
<li>TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims</li>
<li>The 500+ gene biomarker test advances access to localized precision oncology for patients</li>
</ul>
SAN DIEGO, Aug. 27, 2024 /PRNewswire/ --&nbsp;Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro&nbsp;diagnostic (IVD)&nbsp;TruSight&#x2122; Oncology (TSO) Comprehensive test and its first two&nbsp;companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying&nbsp;an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. TSO Comprehensive is FDA approved as a CDx to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions that may benefit from treatment with Bayer's VITRAKVI&#xAE; (larotrectinib). The test is also approved to identify adult patients with locally advanced or metastatic rearranged during transfection (RET)&nbsp;fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Lilly's RETEVMO&#xAE; (selpercatinib).

FDA Approves Illumina Cancer Biomarker Test With Two Companion Diagnostics To Rapidly Match Patients To Targeted Therapies

Mirum Pharmaceuticals, Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mirm#NASDAQ">MIRM</a>) lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (&quot;IBAT&quot;) inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) worldwide. Sales of Livmarli have been rising steadily since its approval and launch in 2021.
The FDA approved a label expansion for Livmarli oral solution to include the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (&quot;PFIC&quot;) in March.
Also, during the second quarter of 2024, Livmarli was approved for treating cholestatic pruritus in PFIC patients aged 12 months and above in the United States.
The European Commission approved Livmarli for the treatment of PFIC in patients aged three months and older in July.
In the first half of 2024, Livmarli generated sales worth $90.1 million, up 46.3% on a year-over-year basis. The label expansion and the continuous demand for the drug should drive sales further in the days ahead.
Shares of Mirum have rallied 37.8% year to date against the industry&#39;s decrease of 1.7%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fe/74613.jpg?v=1754235886" />
Image Source: Zacks Investment Research
In June 2024, Mirum submitted a new drug application for chenodiol for treating cerebrotendinous xanthomatosis patients in the United States.
Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for the treatment of CTX, a rare autosomal genetic disorder.
We remind investors that in August 2023, Mirum acquired all assets of Travere Therapeutics&#39; bile acid products, which added two other products to its commercial portfolio &mdash; Cholbam (cholic acid) capsules and Chenodal (chenodiol) tablets. Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders.
The addition of these two commercialized products helps Mirum to diversify its revenue stream.
This apart, MIRM is developing its pipeline candidate, volixibat, an oral IBAT inhibitor, in two separate phase IIb studies for the treatment of primary biliary cholangitis and primary sclerosing cholangitis.
If successfully developed and upon potential approval, volixibat may provide a novel approach to the treatment of adult cholestatic diseases.
The continued demand for Livmarli and the addition of Cholbam and Chenodal should help Mirum establish a leading pediatric hepatology franchise. However, the company remains heavily dependent on Livmarli for revenues, which is a concern. Any regulatory setback for the drug will hurt the company&#39;s growth prospects.
Also, any developmental setback related to the pipeline will have an adverse effect on the company&#39;s growth prospects. Also, it remains to be seen whether Cholbam and Chenodal are able to reduce the heavy dependence on Livmarli for revenues in the days ahead.
<div class="chart_embed">
<h3>Mirum Pharmaceuticals, Inc. Price and Consensus</h3>
<img alt="Mirum Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/d0/1724073918.png" style="height:265px; width:581px" title="" />
Mirum Pharmaceuticals, Inc. price-consensus-chart | Mirum Pharmaceuticals, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Mirum currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), both sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.07 to $3.16. Earnings per share estimates for 2025 have improved from $2.93 to $4.49. Year to date, shares of ILMN have lost 6.4%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have surged 36.9%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2323868/mirum-mirm-banks-on-livmarli-overdependence-a-concern?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2323868">To read this article on Zacks.com click here.</a>

MIRM

Mirum Banks on Livmarli, Overdependence a Concern

The S&amp;P 500 and Nasdaq 100 extended their upward streak on Monday, both logging a robust eight consecutive sessions in positive territory as traders maintain optimism about the U.S. economic outlook and improving financial conditions ahead of the Federal Reserve&#8217;s <a href="https://www.benzinga.com/topic/interest-rates">anticipated rate-cut cycle.</a>
For the S&amp;P 500, this marks its longest winning streak since May 2024, while the tech-heavy Nasdaq 100 hasn&#8217;t seen such a run since October 2023.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed Monday&#8217;s session up 0.95%, bringing it within just 1% of its all-time high reached in mid-July. Nearly 95% of S&amp;P 500 companies have reported second-quarter results. FactSet data shows that 79% of these firms have exceeded earnings-per-share (EPS) expectations, and 60% have posted higher-than-expected revenue. The S&amp;P 500's blended year-over-year earnings growth rate is at 10.9%, the strongest since Q4 2021.
The Nasdaq 100, monitored through the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), closed 1.3% higher, but it remains 4.6 percentage points below its record highs. 
&#8220;Last week saw unfounded US recession fears and global financial market jitters go poof as quickly as they arrived,&#8221; wrote veteran Wall Street investor Ed Yardeni in a note Monday. 
Monday&#8217;s session saw no economic data releases, but investors responded positively to comments from Minneapolis Federal Reserve President Neel Kashkari, a well-known hawk, who hinted at the possibility of a rate cut in September during an exclusive interview with The Wall Street Journal.
Market-implied probabilities currently indicate a 77.5% chance of a 25-basis-point rate cut in September, with a 22.5% likelihood of a larger 50-basis-point cut, according to CME Group FedWatch tool. 
This week, traders will be closely watching key monetary policy discussions at <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40446287/investors-look-for-clues-on-september-rate-cut-at-jackson-hole-how-does-stock-mar">the Jackson Hole Symposium</a>, scheduled for Aug. 22-24, where Fed Chair Jerome Powell is set to speak on Friday at 10 a.m.
&#8220;If the Fed eases too much and doesn't push back against expectations of more rate cuts to come, the yen could strengthen again, triggering a second wave of unwinding carry trades,&#8221; Yardeni warned. 
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</td>
<td>4.93</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>4.52</td>
</tr>
<tr>
<td>Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)</td>
<td>4.41</td>
</tr>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>4.31</td>
</tr>
<tr>
<td>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>4.31</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Nasdaq 100&#8217;s Top Performers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>4.52</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>4.31</td>
</tr>
<tr>
<td>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</td>
<td>4.25</td>
</tr>
<tr>
<td>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>4.10</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>3.62</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40439485/goldman-sachs-cuts-us-recession-odds-to-20-reverses-earlier-increase-as-economic-">Goldman Sachs Cuts US Recession Odds To 20%, Reverses Earlier Increase As Economic Data Improves</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers

AN2 Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/antx#NASDAQ">ANTX</a>), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.
The company is currently evaluating its lead clinical-stage candidate, epetraborole, a bacterial leucyl-tRNA synthetase inhibitor, for nontuberculous mycobacteria (NTM) lung disease and acute melioidosis in separate early-stage studies.
In the past month, shares of AN2 Therapeutics plunged 66.3% after the company announced that it has discontinued its mid to late-stage study on epetraborole for patients with treatment-refractory mycobacterium avium complex lung disease due to unsatisfactory efficacy results.
Year to date, shares of ANTX have plummeted 95.2% compared with the industry&#39;s 1.7% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/50/74594.jpg?v=2118867417" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
On Aug 8, AN2 Therapeutics announced top-line results from the phase II portion of the phase II/III EBO-301 study evaluating epetraborole in combination with an optimized background regimen (OBR) in treatment-refractory MAC lung disease.&nbsp;
Per ANTX, the EBO-301 study met its primary endpoint, potentially validating a novel patient-reported outcome&nbsp;tool and a higher PRO-based clinical response rate of 39.5% in the epetraborole arm compared with the 25% observed in the placebo arm, when combined with OBR.
However, the MAC lung disease study failed to demonstrate a statistically significant, superior sputum culture conversion at month six, a key secondary endpoint, in the epetraborole + OBR arm compared with the placebo + OBR arm. On the contrary, the sputum culture conversion at month six was similar between the treatment arms.
We remind the investors that in February 2024, AN2 Therapeutics had voluntarily suspended new patient enrollment in the phase III portion of the EBO-301 study due to potentially lower-than-expected efficacy observed in blinded aggregate data.
Following the latest data from the phase II/III study announced in August, the company terminated the phase II as well as the phase III portion of the EBO-301 study.
AN2 Therapeutics clarified that the candidate was generally well-tolerated, and the study was not terminated due to safety concerns.
Following the massive setback, the company will further evaluate the EBO-301 study results to determine the next steps for the potential future development of epetraborole to treat NTM lung disease in other patient populations.
The company also plans to invest heavily in research and developmental activities to accelerate the development of several pre-clinical candidates for infectious diseases and oncology. Simultaneously, AN2 Therapeutics plans to undergo strategic restructuring with the intent of extending its cash runway through 2027.
In an SEC filing, the company stated that it will slash its workforce by approximately 50% by the end of 2024, as part of its strategic restructuring efforts. ANTX anticipates the charges for such a reduction in workforce in the range of $2-$3 million, including severance and other employee-termination related expenses.
Currently, AN2 Therapeutics is gearing up to initiate a phase I clinical study of its second product candidate, AN2-502998, to cure chronic Chagas disease. The company is also planning to initiate a mid-stage study of epetraborole for the melioidosis indication.
<div class="chart_embed">
<h3>AN2 Therapeutics, Inc. Price and Consensus</h3>
<img alt="AN2 Therapeutics, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/94/1724071843.png" style="height:310px; width:600px" title="" />
AN2 Therapeutics, Inc. price-consensus-chart | AN2 Therapeutics, Inc. Quote
</div>
<h3>Zacks Rank &amp; Other Stocks to Consider</h3>
AN2 Therapeutics currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the overall healthcare sector include&nbsp;Illumina, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>),&nbsp;Fulcrum Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) and&nbsp;Arcturus Therapeutics&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.07 to $3.16. Earnings per share estimates for 2025 have improved from $2.93 to $4.49. Year to date, shares of ILMN have lost 6.4%.
Illumina&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, the consensus estimate for Fulcrum Therapeutics&#39; 2024 loss per share has narrowed from $1.24 to 48 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.51 during the same period. Year to date, shares of FULC have jumped 36.9%.
Fulcrum Therapeutics beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 393.18%.
In the past 60 days, estimates for Arcturus Therapeutics&#39; 2024 loss per share have improved from $4.39 to $2.60. The estimate for 2025 is currently pegged at earnings of 21 cents per share. Year to date, shares of Arcturus Therapeutics have lost 35.9%.
Earnings of Arcturus Therapeutics beat estimates in each of the last four quarters, delivering a four-quarter average earnings surprise of 56.73%.
<a href="https://www.zacks.com/stock/news/2323887/an2-therapeutics-antx-plunges-66-in-a-month-here-s-why?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2323887">To read this article on Zacks.com click here.</a>

ANTX

ARCT

AN2 Therapeutics Plunges 66% in a Month: Here's Why

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Benchmark analyst Todd Brooks downgraded the rating for Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from Buy to Hold. Chuy&#8217;s shares fell 0.03% to close at $37.10 on Friday. <a href="https://www.benzinga.com/quote/chuy/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Brian Mullan downgraded Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) from Overweight to Neutral and announced a price target of $114. Shake Shack shares fell 1.9% to close at $107.37 on Friday. <a href="https://www.benzinga.com/quote/shak/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank analyst Tanya Jakusconek downgraded the rating for AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) from Sector Perform to Sector Underperformm but raised the price target from $27 to $30. Anglogold Ashanti shares gained 3.5% to close at $31.47 on Friday. <a href="https://www.benzinga.com/quote/au/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Erik Woodring downgraded the rating for HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) from Overweight to Equal-Weight and announced a price target of $37. HP shares gained 1.2% to settle at $35.91 on Friday.<a href="https://www.benzinga.com/quote/hpq/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Brian Mullan downgraded Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from Overweight to Neutral and announced a price target of $36. Dutch Bros shares gained 1% to close at $32.64 on Friday. <a href="https://www.benzinga.com/quote/hpq/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
</ul>
Considering buying HPQ stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19090055/image-153-1024x578.png" alt="" class="wp-image-501463" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19090055/image-153-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19090055/image-153-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19090055/image-153-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/19090055/image-153.png 1197w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40437625/around-2m-bet-on-this-health-care-stock-check-out-these-3-stocks-under-5-insiders-are-ag">Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying</a></li>
</ul>

Downgrades

BROS

CHUY

SHAK

This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="https://www.benzinga.com/analyst-stock-ratings"> analyst ratings page.</a>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5809becc846faa000106ad2b/stephen-bersey">HSBC analyst Stephen Bersey</a> upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Hold to Buy, while raising the price target from $46 to $58. Cisco shares gained 6.8% to close at $48.53 on Thursday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Williams Trading analyst Sam Poser upgraded NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Sell to Buy and boosted the price target from $67 to $93. Nike shares gained 5.1% to close at $82.50 on Thursday. <a href="https://www.benzinga.com/quote/CNKESCO/analyst-ratings">See how other analysts view this sto</a>ck.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6331beac10b15f0001b58380/c-j%20muse">Cantor Fitzgerald analyst C J Muse </a>upgraded the rating for Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) from Neutral to Overweight and announced a $160 price target. Teradyne shares gained 5.2% to close at $131.73 on Thursday. <a href="https://www.benzinga.com/quote/TER/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Harsh Kumar upgraded Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from Neutral to Overweight, while increasing the price target from $90 to $100. Microchip shares gained 4.1% to settle at $81.30 on Thursday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Daiwa Capital analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6331beac10b15f0001b58380/c-j%20muse">Narumi Nakagiri</a> upgraded the rating for Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Neutral to Buy and boosted the price target from $120 to $154. Illumina shares gained 5.3% to close at $128.80 on Thursday. See how other analysts view this stock. S<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-1024x579.png" alt="" class="wp-image-498819" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47.png 1257w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

Pre-Market Outlook

CSCO

MCHP

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more… Over the past two decades, the cost of gene sequencing has plummeted, turning genomics into a cutting-edge field with enormous potential. Thanks to substantial investments and waves of research funding, the industry is making significant strides in understanding and treating a range of genetic disorders and complex diseases.
In this rapidly evolving landscape, fundamentally sound companies like Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>) are at the forefront of transforming healthcare.
Genomics is not just about unlocking the secrets of DNA; it's about applying that knowledge to real-world medical treatments. By understanding the unique genetic code of individuals, doctors can now offer more precise diagnostics and personalized treatments for conditions that range from common cancers to rare genetic disorders. It's an approach that brings us closer to an era of truly personalized medicine, where your DNA guides your healthcare plan.
Sales of next-generation genomic medicines are expected to <a href="https://ascent.usbank.com/private-capital-management/ascent-resources-and-insights/investment-strategies/investing-in-genomics.html">hit $84 billion by 2028</a>, driven by successful clinical trials and the growing need for new treatments. Moreover, the global genomics market is projected to grow from $39.53 billion in 2024 to $157.47 billion by 2033 at a <a href="https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033#:~:text=The%20global%20genomics%20market%20size,period%20(2024%2D2033).">CAGR of 16.6%</a>.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On April 30, 2024, ALNY and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced a further expansion of their existing partnership in Central &amp; Eastern Europe and Israel also to include selected markets in LATAM and APAC and additional international markets.
This partnership is expected to ensure that ALNY's commercial therapies are available across multiple international markets, thus enhancing their income streams.
ALNY's trailing-12-month gross profit and EBIT margins of 87% and 4.38% are 50.5% and 64.7% higher than their respective industry averages of 57.81% and 2.66%. Also, its trailing-12-month levered FCF margin of 18.10% compares to the industry average of 1.60%.
During the fiscal second quarter that ended June 30, 2024, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million versus a year-ago operating loss of $154.03 million. Also, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded last year.
Analysts predict ALNY's revenue for the current year (ending December 2024) to increase 20.5% year-over-year to $2.20 billion. Further, its revenues are expected to register a 13.2% growth from the prior year, settling at $2.49 billion. It is no surprise that the company has topped the consensus revenue estimates in three of the trailing four quarters.
Over the past six months, ALNY's stock has surged 85.3% to close the last trading session at $273.15.
ALNY's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Sentiment and a B for Quality. ALNY is ranked #28 among 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #2: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN develops, manufactures, and markets life science tools and integrated systems for large-scale genetic variation and function analysis. It operates through the Core Illumina and GRAIL segments. It provides sequencing and array-based instruments and consumables, whole-genome sequencing, genotyping, NIPT, and product support services.
On July 9, the company acquired Fluent BioSciences, a company known for its advanced single-cell technology. This acquisition strengthens ILMN's multiomics growth strategy by offering its customers advanced capabilities in single-cell research and enabling them to provide more comprehensive solutions to their customers.
ILMN's trailing-12-month EBIT margin of 4.63% is 80% higher than the industry average of 2.57%. Likewise, its 14.34% trailing-12-month EBITDA margin is 132.7% above the industry average of 6.16%. Also, its trailing-12-month levered FCF margin of 19.39% compares to the industry average of 1.61%.
In the second quarter that ended June 30, 2024, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. The company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
Street expects ILMN's EPS for the fiscal third quarter (ending September 2024) to increase 164.7% year-over-year to $0.87, while its revenue is forecasted to be $1.08 billion. Moreover, it surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $130.97.
ILMN's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It also has a B grade for Growth, Sentiment, and Quality. Within the same industry, it is ranked #24. To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #1: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Its product portfolio includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara solution, and ARCALYST, among other injections.
On September 13, the U.S. Food and Drug Administration (FDA) approved the use of Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older.
The stock's trailing-12-month EBITDA and levered FCF margins of 33.50% and 15.50% are considerably higher than the industry averages of 6.16% and 1.61%, respectively. Similarly, its trailing-12-month EBIT margin of 30.14% compares to the industry average of 2.57%.
REGN's net revenues for the second quarter (ended June 2024) increased 12% year-over-year to $3.55 billion. Its non-GAAP net income grew 14.3% from the year-ago value to $1.35 billion, while its income from operations stood at $1.07 billion, up 5.2% year-over-year. The company's non-GAAP net income per share came in at $11.56, representing a 12.9% year-over-year growth.
The consensus revenue estimate of $3.66 billion for the fiscal third quarter (ending September 2024) represents an 8.7% improvement year-over-year. The consensus EPS estimate of $11.76 for the ongoing quarter represents a 1.5% increase from the same period last year. The company has a promising earnings surprise history, as it surpassed the consensus EPS estimates in three of the trailing four quarters.
Shares of REGN have gained 38.1% over the past year and 29.7% year-to-date.
It is no surprise that REGN has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Value and Quality. Out of 335 stocks in the same industry, it is ranked #8.
In addition to the POWR Rating grades I've just highlighted, you can see REGN's Growth, Momentum, Stability, and Sentiment ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
REGN shares were unchanged in premarket trading Thursday. Year-to-date, REGN has gained 29.66%, versus a 18.86% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/regn-alny-ilmn-3-genomics-stocks-transforming-healthcare/>3 Genomics Stocks Transforming Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomics Stocks Transforming Healthcare

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA drug approvals. Thus, investing in Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), and Gilead Sciences (GILD) could be a golden opportunity for those looking to ride the wave of future breakthroughs. Read on… With rapid innovations in biotechnology, companies are developing groundbreaking therapies and diagnostic tools that address chronic diseases and improve patient outcomes. This continuous advancement is not only enhancing healthcare quality but also attracting attention from investors seeking to capitalize on the sector's transformative potential.
Amid this backdrop, fundamentally robust biotech stocks such as Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) could offer significant return potential owing to their pipelines that are awaiting FDA approvals.
The biotechnology industry is experiencing significant growth, driven by increasing demand for personalized medicine and breakthroughs in treating chronic diseases. The approval of new drugs by the Food and Drug Administration (FDA) has also played a crucial role in this expansion.
This year alone, the FDA has <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approved 30 novel drugs</a> targeting conditions ranging from lung cancer to Alzheimer's disease and various other chronic ailments.
A recent survey by GlobalData highlights this positive momentum, revealing that <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">44% of healthcare industry professionals</a> worldwide feel optimistic or extremely optimistic about the recovery of biotech funding in the upcoming twelve months. This sentiment reflects confidence in the sector's ability to innovate and meet rising healthcare demands.
Additionally, ongoing advancements and advanced diagnostics are propelling the biotechnology field forward. The transformative potential of Generative AI in drug discovery further amplifies this growth.
According to the McKinsey Global Institute, Generative AI could contribute <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">up to $110 billion annually</a> in economic value for the pharmaceutical and medtech sectors, indicating a bright future for biotechnology.
Furthermore, as per a report by Precedence Research, the global biotechnology market is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.5%</a>, reaching approximately $4.61 trillion by 2034.
Considering these factors, let's discuss the fundamentals of three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, starting with #3.
Stock #3: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN provides sequencing- and array-based solutions for genetic and genomic analysis. It operates through two main segments: Core Illumina and GRAIL. The company is also engaged in a research collaboration, option, and license agreement which focuses on discovering novel dual tumor-associated antigens (TAA) that target trispecific antibodies.
On August 27, ILMN <a href="https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=cca694db-8cc7-4b6a-9449-38ccd9329816">received FDA approval</a> for its TruSight&#x2122; Oncology (TSO) Comprehensive test and two companion diagnostic (CDx) indications. The TSO Comprehensive test profiles over 500 genes in solid tumors, increasing the chance of identifying actionable biomarkers for targeted therapies or clinical trials.
The approval could strengthen ILMN's position in oncology diagnostics, likely driving higher demand for its products. The expanded market presence could positively impact its stock price as precision medicine grows.
In the fiscal 2024 second quarter that ended June 24, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. Plus, the company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
ILMN's EPS for the fiscal 2024 third quarter, ending September 2024, is expected to grow 164.8% year-over-year to $0.87. Moreover, the company's EPS for the fiscal 2024 fourth quarter ending December 2024 is forecasted to rise by 573.7% from the prior year's period to $0.94.
In parallel, the company has surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $131.20.
ILMN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
ILMN has a B grade for Growth, Sentiment, and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #28 out of 333 stocks.
To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #2: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On August 30, ALNY <a href="https://investors.alnylam.com/press-release?id=28411">reported detailed results</a> from the Positive HELIOS-B Phase 3 Study of vutrisiran, an investigational RNAi therapeutic for ATTR amyloidosis with cardiomyopathy. The study showed significant improvements in all primary and secondary endpoints. Vutrisiran reduced all-cause mortality and recurrent cardiovascular events by 28%.
With mortality reduced by 31% during the double-blind period and 36% over 42 months, vutrisiran demonstrates strong potential in treating cardiomyopathy. As a key pipeline asset, its success positions ALNY for future market growth. This could strengthen ALNY's portfolio, driving revenue and enhancing investor confidence, which could positively impact its stock price.
On April 7, ALNY <a href="https://investors.alnylam.com/press-release?id=28111">announced positive results</a> from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran. Zilebesiran, added to standard antihypertensives like indapamide, amlodipine, or olmesartan, demonstrated promising outcomes, advancing its development as a potential treatment for hypertension.
As an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT), zilebesiran offers the possibility of biannual dosing. Its success in the pipeline could significantly benefit ALNY by providing a long-acting hypertension treatment, potentially expanding its market presence and driving long-term revenue growth.
During the fiscal 2024 second quarter that ended June 30, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million compared to an operating loss of $154.03 million in the previous year's quarter.
Furthermore, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded in the last year's period.
Analysts predict ALNY's revenue for the fiscal year ending December 2024 to increase 20.5% year-over-year to $2.20 billion. Moreover, the company's revenue for the next fiscal year ending December 2025 is estimated to rise 13.2% from the prior year to $2.49 billion. The company has surpassed the consensus revenue estimates in three of four trailing quarters.
ALNY's stock has surged 53% over the past nine months and 56% over the past year to close the last trading session at $273.88.
ALNY's bright prospects are mirrored in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
ALNY has a B grade for Sentiment and Quality. It is ranked #27 among 333 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer.  Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On September 12, GILD <a href="https://www.gilead.com/news/news-details/2024/gileads-twiceyearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and-demonstrated-superiority-to-daily-truvada">shared interim analysis results</a> from a pivotal Phase 3 clinical trial for lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor. The results revealed a remarkable 96% reduction in HIV infections compared to background HIV incidence (bHIV), positioning lenacapavir as a potential game-changer in HIV treatment and enhancing GILD's reputation in the field.
Earlier, on August 14, GILD <a href="https://www.gilead.com/news/news-details/2024/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda">announced the FDA's accelerated approval</a> of Livdelzi&#xAE; (seladelpar) for treating primary biliary cholangitis (PBC). The treatment, in combination with ursodeoxycholic acid (UDCA), achieved a 25% normalization rate of alkaline phosphatase (ALP) values after 12 months.
This improvement indicates a significant reduction in liver-related complications, enhancing patient outcomes. Together, these developments strengthen GILD's pipeline, potentially driving substantial revenue growth and solidifying its position as a leader in innovative therapies.
For the fiscal 2024 second quarter, which ended on June 30, GILD's total revenues increased 5.4% year-over-year to $ 6.95 billion. The company's non-GAAP operating income came in at $3.27 billion, rising 43.4% from the previous year's quarter.
In addition, its non-GAAP net income attributable to GILD came in at $2.52 billion or $2.01 per share, up 49.2% and 50% year-over-year, respectively.
The consensus revenue and EPS estimates of $27.99 billion and $7.13 for the fiscal year ending December 2025 reflect a rise of 1% and 87.7% year-over-year, respectively. Also, the company has an excellent surprise history; it surpassed the consensus revenue estimates in all four trailing quarters.
GILD's stock has surged 6.8% over the past nine months and 10.7% over the past year to close the last trading session at $83.94.
It's no surprise that GILD has an overall A rating, equating to a Strong Buy in our POWR Ratings system.
GILD has an A grade for Value and a B for Quality. Within the same industry, it is ranked #5.
Beyond what is stated above, we've also rated GILD for Momentum, Stability, Growth, and Sentiment. Get all GILD ratings <a href="https://stocknews.com/stock/GILD/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>  

<hr />
GILD shares rose $0.37 (+0.44%) in premarket trading Monday. Year-to-date, GILD has gained 7.41%, versus a 20.49% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/gild-alny-ilmn-3-biotech-stocks-to-watch-as-fda-approvals-roll-in/>3 Biotech Stocks to Watch as FDA Approvals Roll In</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks to Watch as FDA Approvals Roll In

GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success

Capital Markets' top 30 global ideas for the fourth quarter

Illumina ( ($ILMN) ) has issued an update. Illumina, Inc. has announced that their General Counsel and Secretary, Charles Dadswell, will be leaving...

Illumina Announces Senior Legal Leadership Transition and Compensation

Catalyst Watch: Tesla's Robotaxi reveal, AI events for Nvidia, AMD, and HP Enterprise

ABNB

ACCD

ACWI

AGYS

ALKS

AMZN

ANCTF

APLD

BIDU

BMBLF

BYND

CAPR

CELH

CNSWF

COST

EVRI

FAST

FLUT

FSLR

GDRZF

GILD

GLPI

GOOG

GSAT

HELE

HUBS

LDNXF

MAKSF

MYGN

NAPA

NVNO

PINS

PYPL

RACE

REGN

SAVA

SHEL

SIEGY

SITC

SMAR

TSLA

UBER

VEEV

VLKAF

VSTO

VTNR

ZLDPF

ZLDSF

Press Releases

Illumina to Present Upcoming Strategy Update

Illumina launches new oncology menu for NovaSeq X Series customers

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Illumina announces strategy to accelerate value creation

Sector Spotlight: Top 4 Basket of Diagnostic Stocks (EXAS, GH, ILMN, LUDG)

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

European Court of Justice rules in favor of Illumina in jurisdictional appeal

Charles Dadswell to step down as General Counsel, Illumina initiates search for successor

Comments

Illumina

뉴스

에 대한 최신 뉴스 Illumina (NASDAQ:ILMN) 주식

월요일, 8월 19, 2024

일요일, 6월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌